DE69528355T2 - Doppelschicht-zusammensetzungen aus digalactosyldiacylglycerol enthaltendem galactolipid - Google Patents

Doppelschicht-zusammensetzungen aus digalactosyldiacylglycerol enthaltendem galactolipid

Info

Publication number
DE69528355T2
DE69528355T2 DE69528355T DE69528355T DE69528355T2 DE 69528355 T2 DE69528355 T2 DE 69528355T2 DE 69528355 T DE69528355 T DE 69528355T DE 69528355 T DE69528355 T DE 69528355T DE 69528355 T2 DE69528355 T2 DE 69528355T2
Authority
DE
Germany
Prior art keywords
galactolipid
samples
room temperature
highly viscous
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69528355T
Other languages
English (en)
Other versions
DE69528355D1 (de
Inventor
Anders Carlsson
Bengt Hersloef
Snezana Petrovic-Kaellholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LIPOCORE HOLDING STOCKHOLM AB
Original Assignee
LIPOCORE HOLDING STOCKHOLM AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9400368A external-priority patent/SE9400368D0/xx
Priority claimed from SE9402455A external-priority patent/SE9402455L/xx
Application filed by LIPOCORE HOLDING STOCKHOLM AB filed Critical LIPOCORE HOLDING STOCKHOLM AB
Publication of DE69528355D1 publication Critical patent/DE69528355D1/de
Application granted granted Critical
Publication of DE69528355T2 publication Critical patent/DE69528355T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0053—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L35/00—Food or foodstuffs not provided for in groups A23L5/00 – A23L33/00; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Magnetic Heads (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Organic Insulating Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
DE69528355T 1994-02-04 1995-02-06 Doppelschicht-zusammensetzungen aus digalactosyldiacylglycerol enthaltendem galactolipid Expired - Lifetime DE69528355T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9400368A SE9400368D0 (sv) 1994-02-04 1994-02-04 Glycolipid material
SE9402455A SE9402455L (sv) 1994-07-12 1994-07-12 Biskiktspreparat
PCT/SE1995/000116 WO1995020944A1 (en) 1994-02-04 1995-02-06 Bilayer preparations

Publications (2)

Publication Number Publication Date
DE69528355D1 DE69528355D1 (de) 2002-10-31
DE69528355T2 true DE69528355T2 (de) 2003-05-15

Family

ID=26661955

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528355T Expired - Lifetime DE69528355T2 (de) 1994-02-04 1995-02-06 Doppelschicht-zusammensetzungen aus digalactosyldiacylglycerol enthaltendem galactolipid

Country Status (19)

Country Link
US (1) US6022561A (de)
EP (1) EP0744939B1 (de)
JP (1) JP3203358B2 (de)
CN (1) CN1083713C (de)
AT (1) ATE224704T1 (de)
AU (1) AU691249B2 (de)
CA (1) CA2182576C (de)
DE (1) DE69528355T2 (de)
DK (1) DK0744939T3 (de)
ES (1) ES2183865T3 (de)
FI (1) FI963065A (de)
HU (1) HUT75459A (de)
MY (1) MY113341A (de)
NO (1) NO312494B1 (de)
NZ (1) NZ279953A (de)
PL (1) PL178438B1 (de)
PT (1) PT744939E (de)
TW (1) TW402502B (de)
WO (1) WO1995020944A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005023636A1 (de) * 2005-05-19 2006-11-23 Beiersdorf Ag Wirkstoffkombinationen aus Glucosylglyceriden und Kreatin und / oder Kreatinin
DE102005023640A1 (de) * 2005-05-19 2006-11-23 Beiersdorf Ag Wirkstoffkombinationen aus Glucosylglyceriden und einem oder mehreren partiell neutralisierten Ester von Monoglyceriden und / oder Diglyceriden gesättigter Fettsäuren mit Zitronensäure

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504664C2 (sv) * 1995-09-22 1997-03-24 Scotia Lipidteknik Ab Sätt att framställa fraktionerad olja, oljan, dess användning samt emulsionskomposition innehållande oljan
JP4155601B2 (ja) * 1996-10-25 2008-09-24 モンサント・テクノロジー・エルエルシー 外因性化学物質で植物を処理するための組成物および方法
CN1241902A (zh) * 1996-10-25 2000-01-19 孟山都公司 用外源化学物质处理植物的组合物和方法
US20020016299A1 (en) * 1996-11-08 2002-02-07 Takeshi Sakai Apoptosis inducers
HU225069B1 (en) * 1997-09-09 2006-06-28 Lyotropic Therapeutics Coated particles, methods of making and using
EP1043016B1 (de) 1999-03-30 2014-08-20 Sodic Sa Pflanzenextrakt auf Glycerid-, Phospholipid- und Phytosphingolipidbasis, Verfahren für die Gewinnung dieses Extrakts und ihn enthaltende kosmetische Zusammensetzungen
FR2810540B1 (fr) * 2000-06-21 2004-04-30 C3D Nouvelles preparations cosmetiques ou hygieniques sous forme de dispersion
FR2814071A1 (fr) * 2000-09-21 2002-03-22 Oreal Composition a base de glycoglyceride et ses utilisations notamment cosmetiques
US6890255B2 (en) 2001-12-17 2005-05-10 Igt Multiple wheel roulette game
DE50312971D1 (de) * 2002-04-29 2010-09-23 Biotesys Gmbh Polymerisierte peptid-modifizierte lipide als biologische transportsysteme für mikronutrients
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
DE10336841A1 (de) * 2003-08-11 2005-03-17 Rovi Gmbh & Co. Kosmetische Rohstoffe Kg Kosmetische Zusammensetzung zur Unterstützung des Sauerstofftransports in die Haut
SE0401942D0 (sv) * 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CN103948545B (zh) 2004-05-03 2017-10-03 益普生生物制药公司 用于药物输送的脂质体
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
WO2006067402A2 (en) 2004-12-22 2006-06-29 Lipopeptide Ab Agents inibiting the cathelin-like protein cap18/ll-37
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE102006015544A1 (de) * 2006-03-31 2007-10-04 Kuhs Gmbh Topisch zu applizierende Zusammensetzung
EP2020990B1 (de) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008084253A1 (en) * 2007-01-12 2008-07-17 Lipopeptide Ab Use of a galactolipid for wound and ulcer healing
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20090137497A1 (en) * 2007-11-23 2009-05-28 Beiersdorf Ag Active ingredient combinations of glucosyl glycerides and creatine and/or creatinine
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
WO2009131672A1 (en) * 2008-04-22 2009-10-29 University Of Massachusetts Stabilized liposome compositions and related methods of use
EP2406361B1 (de) * 2009-03-11 2021-01-20 Swedish Oat Fiber AB Verfahren zur trennung von neutralen und polaren lipiden und öl mit hohem gehalt an polaren lipiden
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
JP4717961B2 (ja) * 2009-10-07 2011-07-06 パナソニック株式会社 人工脂質膜形成方法
UA111147C2 (uk) * 2009-11-11 2016-04-11 Байєр Б.В. Способи та композиції для лікування або профілактики зовнішнього отиту
WO2011087403A1 (en) * 2010-01-18 2011-07-21 Lipidor Ab Alcoholysis of glycolipid and corresponding lysis product
DK2575768T3 (en) 2010-05-24 2018-03-12 Swedish Oat Fiber Ab Aqueous Dispersion Comprehensive Galactolipids and Procedures for their Preparation
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2014508166A (ja) 2011-03-17 2014-04-03 トランスダーマル バイオテクノロジ インコーポレーテッド 局所的一酸化窒素システム及びその使用方法
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
EP3362049A1 (de) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd. Stabilisierung von pharmazeutischen camptothecinzusammensetzungen
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CN110183500B (zh) * 2019-07-05 2022-09-09 湖北中医药大学 一种植物半乳糖脂的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437567A (en) * 1890-09-30 Cash and parcel carrier
EP0009842B1 (de) * 1978-10-02 1982-11-10 THE PROCTER & GAMBLE COMPANY Liposome zur Freigabe von Arzneimitteln und eine ein Arzneimittelsystem mit liposomen enthaltende Bereitung
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
CA1320130C (en) * 1986-06-12 1993-07-13 Alan L. Weiner Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US5234767A (en) * 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
ATE92765T1 (de) * 1989-02-06 1993-08-15 Chiba Flour Milling Limulustest-positives pflanzenglykolipid und verfahren zur stimulierung des immunsystems eines tieres.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005023636A1 (de) * 2005-05-19 2006-11-23 Beiersdorf Ag Wirkstoffkombinationen aus Glucosylglyceriden und Kreatin und / oder Kreatinin
DE102005023640A1 (de) * 2005-05-19 2006-11-23 Beiersdorf Ag Wirkstoffkombinationen aus Glucosylglyceriden und einem oder mehreren partiell neutralisierten Ester von Monoglyceriden und / oder Diglyceriden gesättigter Fettsäuren mit Zitronensäure

Also Published As

Publication number Publication date
HU9602146D0 (en) 1996-09-30
PL315779A1 (en) 1996-12-09
JPH09508414A (ja) 1997-08-26
ATE224704T1 (de) 2002-10-15
EP0744939B1 (de) 2002-09-25
AU1723495A (en) 1995-08-21
CA2182576A1 (en) 1995-08-10
PL178438B1 (pl) 2000-04-28
DK0744939T3 (da) 2003-02-03
FI963065A (fi) 1996-09-30
NO312494B1 (no) 2002-05-21
NO963241L (no) 1996-08-02
US6022561A (en) 2000-02-08
AU691249B2 (en) 1998-05-14
CA2182576C (en) 2002-09-17
WO1995020944A1 (en) 1995-08-10
HUT75459A (en) 1997-05-28
DE69528355D1 (de) 2002-10-31
PT744939E (pt) 2003-02-28
NZ279953A (en) 1998-02-26
CN1144478A (zh) 1997-03-05
EP0744939A1 (de) 1996-12-04
FI963065A0 (fi) 1996-08-02
JP3203358B2 (ja) 2001-08-27
MY113341A (en) 2002-01-31
TW402502B (en) 2000-08-21
CN1083713C (zh) 2002-05-01
NO963241D0 (no) 1996-08-02
ES2183865T3 (es) 2003-04-01

Similar Documents

Publication Publication Date Title
DE69528355T2 (de) Doppelschicht-zusammensetzungen aus digalactosyldiacylglycerol enthaltendem galactolipid
Elias et al. Histamine in the insect nervous system: distribution, synthesis and metabolism
Bell Demonstration and characterization of two vitellogenic blood proteins in Periplaneta americana: an immunochemical analysis
Kaitaranta et al. Response and linearity of different lipid compounds when analyzed by thin-layer chromatography with flame ionization detection
ES8606659A1 (es) Un metodo para detectar anticuerpos en suero o fluido
CA2073431A1 (en) Interdigitation-fusion liposomes and gels
KR960705563A (ko) 펜벤다졸 제형(Fenbendazole formulations)
Stevenson et al. Electrophoretic and Chromatographic Investigations of Clay‐adsorbed Organic Colloids: 1. Preliminary Investigations
Macheboeuf et al. Studies on lipo-protein cenapses of horse serum
AU5933080A (en) 1-alkadienyl-2hydroxymethyl-3,4,5-trihydroxy- piperidine compounds
FI951811A0 (fi) Lomisormitus-fuusioliposomit ja -geelit
Fasano et al. Diarrhea in ciguatera fish poisoning: preliminary evaluation of pathophysiological mechanisms
Falk et al. Structural analysis by mass spectrometry and NMR spectroscopy of the glycolipid sulfate from Halobacterium salinarium and a note on its possible function
Cherton et al. Direct in vitro and in vivo monitoring of destruxins metabolism in insects using internal surface reversed-phase high-performance liquid chromatography: I. Behaviour of E destruxin in locusts
ATE198078T1 (de) Antibeschlag-film, verfahren zur verpackung von produkten mit hohem feuchtegehalt und derart verpackte produkte
Weiner et al. Interactions of dimethyl sulfoxide with lipid and protein monolayers
Roozemond et al. Lipid composition and microviscosity of subcellular fractions from rabbit thymocytes. Differences in the microviscosity of plasma membranes from subclasses of thymocytes
Nichols et al. Effect of Lysophosphatidyl Choline on Interaction between Phosphatidyl Choline and Activator Protein (Apolipoprotein AI) of Lecithin: Cholesterol Acyltransferase
TW378271B (en) The method of quantitative analysis of thuringiensin by capillary electrophoresis
Belayouni et al. Glucosamine as a biochemical marker for Dinoflagellates in phosphatised sediments
Takashima et al. Distribution of fluocinolone acetonide in oil-in-water creams and its release from the creams
Toolson CUTICULAR PERMEABILITY AND EPICUTICULAR LIPID COMPOSITION IN THREE ARIZONA SCORPION SPECIES.
Van Der Linde et al. Role of membrane lipid composition in the cytotoxicity of the sesquiterpene lactone eupatoriopicrin
Subrahmanya et al. Effect of salts on the determination of pH by the indicator method in presence of Igepon T
KR870000419A (ko) 나도세척제(nadocleaning) 제조방법

Legal Events

Date Code Title Description
8364 No opposition during term of opposition